Welcome to our dedicated page for REGENERON PHARMACEUTICALS SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
REGENERON PHARMACEUTICALS, INC. (REGN) executive vice president of Commercial, Marion McCourt, reported open-market sales of company common stock under a Rule 10b5-1 trading plan. On September 3, 2026, she sold 1,131 shares at $857.39 per share, and on September 2, 2026, she sold 1,215 shares at $850.00 per share. A separate entry reports 219 shares of common stock held indirectly through a 401(k) plan as of September 2, 2026.
REGENERON PHARMACEUTICALS, INC. (REGN) director Kathryn Guarini reported option-related transactions in the company’s stock. On September 2, 2026, she exercised options for 400 shares at an exercise price of $719.37 per share and sold 400 shares at $850.00 per share, under a Rule 10b5-1(c) trading plan adopted on February 13, 2026. Following the option exercise, she continued to hold options covering 1,158 shares of common stock.
REGENERON PHARMACEUTICALS, INC. (REGN) is named as the issuer in a Rule 144 notice covering a proposed sale of common stock for the account of officer Marion McCourt. The notice relates to 1,131 shares, to be sold through UBS Financial Services Inc. on NASDAQ.
The shares were acquired from the issuer via RSA vesting on December 12, 2023. The filing also lists a prior sale by Marion McCourt of 1,215 shares of common stock during the past three months.
REGENERON PHARMACEUTICALS, INC. (REGN) reports that company officer Marion McCourt has filed a notice under Rule 144 to sell up to 1,215 shares of Regeneron common stock through UBS Financial Services Inc. on or after September 2, 2026 on NASDAQ. The shares relate to vested restricted stock awards from February 12, 2023, December 9, 2024, and December 16, 2024, with an aggregate value of $1,032,750 reported in the notice.
REGENERON PHARMACEUTICALS, INC. (REGN) is named as the issuer in a Form 144 notice covering a proposed sale of its common stock by director Kathryn Guarini. The notice reports a planned sale of 400 shares of common stock on or after September 2, 2026, with an aggregate market value of $340,000, to be effected through UBS Financial Services Inc.
The shares are indicated as being issuable upon the exercise of a stock option on September 2, 2026, for cash. The filing also reports that Guarini sold 400 shares of Regeneron common stock on August 10, 2026, with an aggregate market value of $320,000, during the prior three months.
REGENERON PHARMACEUTICALS, INC. (REGN) reported insider equity transactions by Joseph J. LaRosa, EVP General Counsel and Secretary. On 2026-08-19, he exercised a non-qualified stock option for 12,282 shares of common stock at an exercise price of $381.92 per share, from an award that vested in four equal annual installments commencing one year after grant. He acquired 12,282 common shares upon exercise and 9,019 shares of common stock at $830.15 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, he directly held 12,283 non-qualified stock options expiring on 2026-12-16 and indirect common stock holdings of 3,402 shares via a 2024 GRAT, 5,407 shares via a 2025 GRAT, and 413 shares through a 401(k) plan.
REGENERON PHARMACEUTICALS, INC. (REGN) reported that EVP Finance and CFO Christopher R. Fenimore exercised a non-qualified stock option for 6,283 shares of common stock on 2026-08-18 at an exercise price of $381.92 per share. The stock option award vested in four equal annual installments. In connection with the exercise, 4,599 shares of common stock were delivered or withheld at $813.47 per share for payment of the exercise price or tax liability. Following the transaction, Fenimore had 6,000 stock options remaining from this grant and held additional shares indirectly through a 401(k) plan and several trusts.
REGENERON PHARMACEUTICALS, INC. director Kathryn Guarini exercised 400 non-qualified stock options for Common Stock at an exercise price of $719.37 per share on August 10, 2026, leaving 1,558 options outstanding that expire on January 2, 2035.
The 400 acquired shares were then sold at $800.00 per share the same day. The disposition and acquisition were made pursuant to a Rule 10b5-1(c) trading plan adopted on February 13, 2026.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported an option exercise-and-sale on August 10, 2026. She exercised 800 Non‑Qualified Stock Options for 800 shares of Common Stock at an exercise price of $376.6900 per share, fully exhausting this option grant, and then sold the 800 acquired shares. All transactions were made under a Rule 10b5‑1(c) trading plan adopted on November 20, 2025.